MAYOLY SPINDLER Committed to your health. Every day. 19-INS-319
OUR AMBITION Become an international reference in gastroenterology and dermo-cosmetics 2
CONTENTS OUR ASSETS OUR FIELDS OF OUR EMPLOYEES’ EXPERTISE COMMITMENT A French company Pharmaceuticals Our values An independent company Diagnostic A responsible company An extensive global footprint Dermo-cosmetics Contract Development & Manufacturing 3 CORPORATE PRESENTATION 08/07/2019
OUR ASSETS a French company ▪ Three manufacturing facilities near Paris, 1 in Chatou (West of Paris) and 2 in Dammarie-les-Lys (East of Paris). ▪ Over 900 employees worldwide, including nearly 600 in France. ▪ Turnover: €182 million in 2018. ▪ 70% of products sold are made in France. ▪ An economic player contributing to France’s status as one of the world’s leading pharmaceuticals exporters*. ▪ Exported production : €51 million * Source: LEEM (French Pharmaceutical Companies Association) – Economic report, 2016 issue. 4 CORPORATE PRESENTATION 08/07/2019
OUR ASSETS NET CONSOLIDATED TURNOVER an independent company 2009- 2018 (€ million) 190 200 182 173 167 180 161 159 154 160 145 ▪ Founded in 1909 : for more than a century, an 138 140 126 entrepreneurial adventure. 120 100 ▪ Still an entirely family-owned company. 80 60 ▪ Financial independence, a main performance driver. 40 20 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 5 CORPORATE PRESENTATION 08/07/2019
OUR ASSETS an extensive global footprint ▪ Established worldwide in more than 70 countries generating 41% of overall turnover ▪ Dynamic subsidiaries: in Europe, Eastern Europe, Asia and Latin America (26% of international turnover in 2018) ▪ Business partners committed for the long term ▪ A proactive development policy ▪ With the acquisition in 2016 of Kibion , a Swedish company principally operating in Germany and the Middle East, Subsidiaries Mayoly Spindler has become one of the world leaders in the detection and control of Helicobacter pylori infections . Distributors 6 CORPORATE PRESENTATION 08/07/2019
OUR FIELDS OF EXPERTISE 7
PHARMACEUTICALS 8
PHARMACEUTICALS BREAKDOWN OF TURNOVER Our historical pillar of development BY BUSINESS SECTOR IN 2018 ▪ Pharmaceutical sector: 72% of overall turnover in Diagnostic CDMO* 13 million € 12 million € 2018 ▪ Gastroenterology : 80% of our pharmaceutical 7 % Dermo-cosmetics 7 % 26 million € business. 13 % ▪ A portfolio of therapeutic solutions spanning speciality care, primary care and self-medication. 72 % ▪ An investment in collaborative R&D in gastroenterology. Pharmaceuticals 131 million € * Contract Development & Manufacturing Organization 9 CORPORATE PRESENTATION 08/07/2019
OUR THERAPEUTIC SOLUTIONS PORTFOLIO IN GASTROENTEROLOGY OTC Rx Biliary lithiasis Acid reflux Biliary cirrhosis Travel sickness Helicobacter pylori Gaz Abdominal pains Digestive and renal elimination functions Crohn’s disease Heartburn Pancreatic insufficiency Cystic fibrosis Probiotics/Gut flora Colonoscopy Constipation 10 10 CORPORATE PRESENTATION 08/07/2019
L’ACTIVITE DIAGNOSTIC DIAGNOSTIC 11 PRÉSENTATION À DESTINATION 08/07/2019 EXCLUSIVE DES INSTITUTIONNELS
DIAGNOSTIC BREAKDOWN OF TURNOVER Our strategic pillar of development BY BUSINESS SECTOR IN 2018 Diagnostic CDMO* 13 million € 12 million € ▪ In 2016 , Mayoly Spindler acquired Kibion, the world 7 % 7 % Dermo-cosmetics leader in fast and reliable urea breath testing machines 26 million € and tests for the diagnosis and eradication control of 13 % Helicobacter pylori . ▪ In 2019 , Mayoly Spindler creates Mayoly Diagnostic , the 72 % business unit dedicated to the devlopment of the Helicobacter pylori infection diagnosis business. Pharmaceuticals 131 million € * Contract Development & Manufacturing Organization 12 08/07/2019 08/07/2019 CORPORATE PRESENTATION
DIAGNOSTIC Our strategic pillar of development ▪ 95% of duodenal ulcers and 70% of gastric ulcers are attributable to Helicobacter pylori ’s infection. ▪ Nearly 4 billion people worldwide are infected. 13 08/07/2019 08/07/2019 CORPORATE PRESENTATION
DERMO-COSMETICS 14
DERMOCOSMETICS BREAKDOWN OF TURNOVER Topicrem, the science of hydration BY BUSINESS SECTOR IN 2018 ▪ Topicrem: n°1 in body moisturizing milks in Diagnostic CDMO* 13 million € pharmacies in France since 2013*. 12 million € Dermo-cosmetics 26 million € ▪ High-quality manufacturing standards recognized 7 % 7 % on an international level. 13 % ▪ All worldwide production of Topicrem is made in France (Dammarie-Les-Lys). 72 % ▪ An international brand (50% of Topicrem sales generated outside of France). Pharmaceuticals 131 million € * Source : IQVIA — Pharmatrend PharmaOne (2016-2018) Pharmatrend NMNM (2013-2016) — marché des hydratants émollients corps femme en lait/lotion — 2013 a 2018 — en volume. * Contract Development & Manufacturing Organization 15 CORPORATE PRESENTATION 08/07/2019
PRODUCTION & CONTRACT MANUFACTURING 16
PRODUCTION & CONTRACT MANUFACTURING BREAKDOWN OF TURNOVER BY BUSINESS SECTOR IN 2018 Technical prowess and responsiveness Diagnostic CDMO* ▪ Three manufacturing facilities near Paris, 1 in 13 million € 12 million € Chatou (West of Paris) and 2 in Dammarie-les-Lys (East 7 % Dermo-cosmetics of Paris). 26 million € 7 % ▪ A softgel capsules expertise requiring a particular 13 % technicality. ▪ A light and reactive structure that adapts to the 72 % requirements of our customers. Pharmaceuticals 131 million € * Contract Development & Manufacturing Organization 17 CORPORATE PRESENTATION 08/07/2019
PRODUCTION & CONTRACT MANUFACTURING Technical prowess and responsiveness ▪ A diversified offer: pharmaceuticals, nutraceuticals, dermocosmetics ▪ Various galenic forms : soft capsules, tablets, capsules, suppositories, oils, emulsions, gel, micellar solutions… 18 CORPORATE PRESENTATION 08/07/2019
OUR EMPLOYEES’ COMMITMENT, CENTRAL TO OUR SUCCESS 19
OUR VALUES RESPONSIBILITY PRAGMATISM RESPECT Our performance is the result of the talent of our employees who, every day, share ambitious projects and a test for challenge . Our corporate culture is reflected in the empowerment of our teams , the opportunity to take initiatives and the pragmatism of each individual. Mayoly Spindler is a company where respect goes hand-in-hand with growth , fostering the well-being of everyone. 20 CORPORATE PRESENTATION 08/07/2019
A RESPONSIBLE COMPANY ▪ OUR MAYOLY, our corporate responsibility programme. ▪ Three priorities: workplace well-being, commitment to the community and care for the environment. ▪ Projects designed and coordinated by employees , working in the general interest. 21 CORPORATE PRESENTATION 08/07/2019
MAYOLY SPINDLER AT A GLANCE 22
41% €182 million of turnover generated turnover outside of France. Pharmaceuticals: 72% Diagnostic : 7% Dermo-cosmetics: 13% Production: 7% Over 900 3 production sites employees worldwide, near Paris: 1 in Chatou including 600 in France. and 2 in Dammarie-les-lys 23 Figures as at 12/31/2018.
Committed to your health. Every day.
Recommend
More recommend
